58 results were returned
By decisions dated 30 July 2018, then confirmed in the appeal by decisions dated 30 August 2018, the Court of Milan dismissed PI requested by ICOS and its licensee Eli Lilly against Sandoz, ascertaining the prima facie ...
The Dutch competition authority, ACM, initiated a market study in 2018 into the effect of the introduction of biosimilars on the competition between TNF alfa inhibitors. TNF-alfa inhibitors are biological medicines that ...
On September 26, 2019, the Higher Regional Court of Düsseldorf confirmed on appeal that Teva Pharmaceutical Industries Ltd. (“Teva”) – one of Bird & Bird’s key clients – is entitled to a preliminary injunction against ...
If a patentee undertakes actions with respect to a patent of the same patent family (e.g. waiving the parent patent of a divisional patent), this is often negatively characterised as playing the “Divisional Game”. We ...
In the last five decades we have been assisting on the digitalization of society and consequently of the healthcare sector; we have been using terms such as eHealth, medical informatics, health informatics, ...
Sanofi sought a compulsory licence for the distribution of its high cholesterol drug Praluent® but this was dismissed in preliminary proceedings (docket no: 3 LiQ 1/18).
The French so-called “anti-gift” provisions strictly frame the conditions under which companies in the health sector are allowed to provide advantages, in cash or in kind, to healthcare professionals ("HCPs”)
The world's most popular banana is dying. Scientists are using the gene-editing mechanism CRISPR to try and save it from extinction.
Following seminal “denigration” cases from the French, Danish and Italian competition authorities, our competition team looks into this new practice of exclusionary abuse.
The Bill of the Law on the organization and transformation of the French healthcare system at the French parliament, adoption of the final version is expected for the end of July.